Reviewer’s report

Title: Efficacy and safety of moxifloxacin in community acquired pneumonia: a prospective, multicenter, observational study (CAPRIVI)

Version: 1 Date: 15 March 2014

Reviewer: Françoise Van Bambeke

Reviewer’s report:

This paper describes the safety and efficacy of moxifloxacin in hospitalized CAP patients in relationship with the severity score. Globally the paper is well written and the data sound robust. I have however some comments for improvements.

MAJOR COMMENTS
1. The introduction and methods section are quite long and could be shortened.
2. The severity score is globally low, but a large proportion of patients was hospitalized because of concomitant diseases, which may explain this low score. What was the score for those patients who were hospitalized primarily for CAP?
   This issue needs to be discussed in more details.
3. Many patients received previous antibiotic treatment. Should this be considered as a confounding factor for efficacy?
4. Statistical analysis is not presented in Tables and figures. This should be done.
5. There is no illustration at all for safety data, which represented however one of the study objectives.

MINOR COMMENTS
1. The introduction mention American therapeutic guidelines for treatment and not European ones. As the study was conducted in Europe, I would recommend adding this piece of information.
2. In the methods, the criteria for diagnostic of CAP should be mentioned, and especially how it was distinguished from bronchitis.
3. The criteria used to decide whether some centres had to be discarded because of suspicion of fraud should be explicited.
4. At the bottom of page 16, what is the difference between 'withdrawn' and 'interrupted'? Does the later mean that treatment was restarted with the same drug once the adverse effect has disappeared?
5. The last paragraph of Table 1 duplicates figure 2.
6. The caption and title of table 2 are unclear and do not reflect the content of the table.
7. The way table 3 is presented is not optimal. I would have done 1 row/bug, with different columns for S, I, R, not determined
8. Figure 2 and Figure 4 would be better represented as pie charts.

**Level of interest:** An article of importance in its field

**Quality of written English:** Acceptable

**Statistical review:** Yes, and I have assessed the statistics in my report.

**Declaration of competing interests:**

I have received research grants from Bayer, but for laboratory work (activity of moxifloxacin in in vitro models of persistent infections)